XERS — Xeris Biopharma Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1867096 ·
Last close
$6.79
Market Cap
$1.17B
52W High
$7.08
52W Low
$5.25
ADV30
1,766,150
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 83,127,000 | 72,553,000 | 7,916,000 | 2,234,000 | 392,013,000 | 111,750,000 | 379,002,000 |
| Dec 2025 | 85,807,000 | 74,860,000 | 16,773,000 | 11,081,000 | 383,527,000 | 111,042,000 | 369,838,000 |
| Sep 2025 | 74,380,000 | 63,384,000 | 6,731,000 | 621,000 | 370,191,000 | 91,598,000 | 371,052,000 |
| Jun 2025 | 71,539,000 | 59,641,000 | 4,482,000 | -1,928,000 | 334,686,000 | 59,285,000 | 353,990,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$28,626,000
Investing CF
$-696,000
Financing CF
$11,389,000
CapEx
$-696,000
Dividends Paid
—
Buybacks
$-10,876,000
EPS Diluted TTM
$-0.01
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-671,307,000
Inventory
$68,673,000
Receivables
$51,050,000
ST Investments
$0
EBIT TTM
$29,638,000
Pretax Income TTM
$554,000
Interest Exp TTM
$29,084,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$314,852,992
EBITDA
$48,080,000
Free Cash Flow
$42,205,376
Enterprise Value
$1,319,042,560
Total Cash
$111,750,000
Total Debt
$258,552,992
Shares Out
172,642,055
Trailing EPS
$0.07
Book Value
$0.08
ROE
—
ROA
6.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 291,845,000 | 24,896,000 | 554,000 | 383,527,000 | 369,838,000 | — | 28,626,000 |
| Dec 2024 | 203,070,000 | -33,646,000 | -54,836,000 | 323,060,000 | 352,675,000 | — | -36,981,000 |
| Dec 2023 | 163,914,000 | -44,010,000 | -62,255,000 | 322,602,000 | 329,384,000 | — | -47,023,000 |
| Dec 2022 | 110,248,000 | -81,940,000 | -94,660,000 | 344,522,000 | 299,335,000 | — | -102,891,000 |
TTM Snapshot
Revenues TTM
$143,373,000
NetIncome TTM
$-75,767,000
OpCashFlow TTM
$0
Assets (Latest)
$323,060,000
Forward EPS
$0.40
Max Pain — expiry 2026-07-17
max pain strike: $5.00 · spot: $6.88 · call oi: 8,694 · put oi: 5,501
Expected Move to 2026-07-17:
±$1.55
(22.53%) —
implied range
$5.33 –
$8.43
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKTS | Aktis Oncology, Inc. | $1.17B | $21.93 | — |
| MPLT | MapLight Therapeutics, Inc. | $1.18B | $27.75 | — |
| EVOTF | Evotec SE | $1.19B | $6.69 | — |
| MNKD | MANNKIND CORP | $1.13B | $3.66 | — |
| WVE | Wave Life Sciences Ltd. | $1.13B | $5.87 | — |
News headlines (Yahoo Finance, 1h cache)
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma
2026-06-12 14:45 · Yahoo
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
2026-06-11 20:39 · Yahoo
Xeris Biopharma Announces Private Exchange of Convertible Notes
2026-06-11 11:00 · Yahoo
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
2026-05-15 11:49 · Yahoo
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
2026-05-09 14:19 · Yahoo
Xeris Biopharma Q1 Earnings Call Highlights
2026-05-09 08:07 · Yahoo
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's Changed
2026-05-08 09:13 · Yahoo
Xeris (XERS) Q1 2026 Earnings Call Transcript
2026-05-07 20:13 · Yahoo
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-05-07 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.